Internet-based tapering of oral corticosteroids in severe asthma: A pragmatic randomised controlled trial

Thorax

Volumn 66, Issue 6, 2011, Pages 514-520

  Hashimoto, Simone ^a   Ten Brinke, Anneke ^b   Roldaan, Albert C ^c   Van Veen, Ilonka H ^d   Möller, Gertrude M ^e   Sont, Jacob K ^e   Weersink, Els J M ^a   Van Der Zee, Jaring S ^a   Braunstahl, Gert Jan ^f   Zwinderman, Aeilko H ^a   Sterk, Peter J ^a   Bel, Elisabeth H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

^c HAGA HOSPITAL   (Netherlands)

^d MEDISCH SPECTRUM TWENTE   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; PREDNISONE;

ADULT; AGED; ARTICLE; ASTHMA; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DIABETES MELLITUS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; GLAUCOMA; HOME MONITORING; HOSPITALIZATION; HUMAN; INTERNET; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TELEMEDICINE; TREATMENT OUTCOME;

EID: 79956341663     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.153411     Document Type: Article

References (35)

1. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000;162:2341-51.
2. Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistant asthma: the needfor an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/ Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999;13:1198-208.
3. Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001;56:279-84. (Pubitemid 32269807)
4. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoidinduced side effects. Ann Rheum Dis 2009;68:1119-24.
5. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-13. (Pubitemid 46210080)
6. National Institutes of Health. National Heart, Lung, and Blood Institute. GlobalInitiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report 2008. http://www.ginasthma.org/ (accessed Oct 2010).
7. McGeehan M, BusseWW.Refractory asthma. Med Clin NorthAm 2002;86:1073-90.
8. Heaney LG, Conway E, Kelly C, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003;58:561-6. (Pubitemid 36808124)
9. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006;117:522-43. (Pubitemid 43340215)
10. Reed CE. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 1999;103:539-47. (Pubitemid 29295555)
11. Dixon RB, Christy NP. On the various forms of corticosteroid withdrawal syndrome. Am J Med 1980;68:224-30. (Pubitemid 10168992)
12. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 2010;376:1838-45.
13. Holbrook A, Thabane L, Keshavjee K, et al. Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. CMAJ 2009;181:37-44.
14. McManus RJ, Mant J, Bray EP, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 2010;376:163-72.
15. Rasmussen LM, Phanareth K, Nolte H, et al. Internet-based monitoring of asthma: a long-term, randomized clinical study of 300 asthmatic subjects. J Allergy Clin Immunol 2005;115:1137-42. (Pubitemid 40824580)
16. van der Meer V, Bakker MJ, van den Hout WB, et al. Internet-based selfmanagement plus education compared with usual care in asthma: a randomized trial. Ann Intern Med 2009;151:110-20.
17. Morlion B, Knoop C, Paiva M, et al. Internet-based home monitoring of pulmonary function after lung transplantation. Am J Respir Crit Care Med 2002;165:694-7. (Pubitemid 34194759)
18. Silkoff PE, Carlson M, Bourke T, et al. The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. J Allergy Clin Immunol 2004;114:1241-56. (Pubitemid 39469172)
19. Krishnan JA, Schatz M, Apter AJ. A call for action: comparative effectiveness research in asthma. J Allergy Clin Immunol 2010;127:123-7.
20. Smith JR, Mildenhall S, Noble MJ, et al. The Coping with Asthma Study: a randomised controlled trial of a home based, nurse led psycho educational intervention for adults at risk of adverse asthma outcomes. Thorax 2005;60:1003-11. (Pubitemid 41705468)
21. Relton C, Torgerson D, O'Cathain A, et al. Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. BMJ 2010;340:c1066.
22. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008;337:a2390.
23. American Thoracic Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med 2005;171:912-30.
24. Juniper EF, Svensson K, Mork AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99:553-8. (Pubitemid 40468501)
25. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-7. (Pubitemid 24034293)
26. Sont JK, Willems LN, Bel EH, et al; The AMPUL Study Group. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999;159:1043-51. (Pubitemid 29202534)
27. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomized controlled trial. Lancet 2002;360:1715-21. (Pubitemid 35447900)
28. Pijnenburg MW, Bakker EM, Hop WC, et al. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005;172:831-6. (Pubitemid 41369065)
29. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73.
30. Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010;138:682-92.
31. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax Published Online First: 11 October 2010. doi:10.1136/thx.2010.135574.
32. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomized controlled trial. Lancet 2008;372:1065-72.
33. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-24.
34. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
35. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93.